Search

Nov 9, 2024
SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies
He describes the Gen 1 data in melanoma and more, and compares it to what we have seen with competitor TIL data. Also, why the Gen 2...

Nov 8, 2024
SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like
Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and...

Nov 7, 2024
Texas Life Science Forum: Reglagene is aiming to get tubulin therapies across the blood brain barrier so they can treat brain cancers
CEO Richard Austin explains how the company hopes to acheive this with a small molecule therapy. Plus, why he moved the company from...

Nov 7, 2024
Texas Life Science Forum: 4M Therapeutics is aiming make therapies for the CNS that are safer and more tolerable than current treatments
CEO Pablo Lapeurta, previously CMO of Lexicon, describes the lead programs for biopolar disorder and Alzheimer's agitation. Plus, Houston...

Nov 7, 2024
Texas Life Science Forum: March Biosciences closed a $28.4M series A round last month to advance its CD5 targeting CAR-T
CEO Sarah Hein describes the rationale for CD5, and share her experience of what it was like making the raise come together. Brought to...

Nov 7, 2024
Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year
CEO Neil Warma describes the unique approach to TCRs that could reduce toxicity and increase persistence compared to other programs....

Nov 7, 2024
Texas Life Science Forum: NKILT Therapeutics is emerging into the in-vivo proof of concept stage of testing its HLA-G targeting cell therapy
CEO Raphaël Ognar describes the progress his company has made over the last year and previews data it will be presenting at SITC and ASH....

Nov 5, 2024
BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24
CEO Erik Manting describes the rationale for focusing on dendritic cell biology, and covers previous data the company has presented in...

Nov 5, 2024
BIO-Europe: Centauri Therapeutics is planning to use antibody recruiting sugars that are linked to a targeting agent to treat infectious disease and cancer
CEO Jennifer Schneider describes how these "Alphamers" are designed to work and discusses the company's upcoming plans to enter the...

Nov 5, 2024
BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology
Executive Chairman Alexander Gebauer describes this approach to aiming to prevent toxic amyloid beta clumps from developing in the first...

Nov 5, 2024
BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year
CEO Mark Gaffney describes the science behind the lead program, CAL101, which targets a Damage Associated Molecular Pattern protein...

Nov 4, 2024
BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting
Elin Trampe describes the unmet need the company believes exists for ED today, the history of their drug and how it was invented in...

Nov 4, 2024
BIO-Europe: The CEO of Sweden's Affibody on trying to be better than antibodies, moving into the radiopharmaceutical space, and IPO rumors
David Bejker describes how affibody's are meant to compete with monoclonal antibodies, which the company's lead program in IL-17. Plus,...

Nov 4, 2024
BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform
Integra CEO Avencia Sánchez-MejÃas and Caszyme CEO Monika PaulÄ— discuss the deal and explain why Cas12l's small size gives it...

Nov 4, 2024
BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward
CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x...

Nov 4, 2024
BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C
CEO Elias Papatheodorou describes the unmet need in liver disease and the rationale for MKK4, a target HepaRegeniX is focused on and is...

Oct 30, 2024
Dallas based Etira is aiming to cause apoptosis in cancer cells by targeting LIPA and thus inducing stress in the endoplasmic reticulum
CEO Russell Hayward describes the scientific rationale of this approach, as well as how the company may be weeks away from dosing its...

Oct 30, 2024
A UT Southwestern neurology expert and the CEO of GenrAb discuss neuro-immunology and finding antibodies that can help with neuronal damage
UTSW's Dr. Ben Greenberg discusses how neuro-immunology is making inroads for conditions like MS, ALS, and alzheimer's. GenrAb CEO Larry...

Oct 29, 2024
Southlake, TX based OncoNano Medicine is harnessing nanotechnology to identify and target cancer - a lead program hits the STING pathway
CFO Matthew Head describes the company's ON-BOARD platform and how they are not only developing therapeutics, but also an imaging product...

Oct 27, 2024
An investigator from MGH and the CSO of Inozyme discuss p1 data at Kidney Week showing that INZ-701 raised the levels of inorganic pyrophosphate, making it a possible treatment for calciphylaxis
Sagar Nigwekar and Yves Sabbagh describe the problem of calciphylaxis, and why they believe that raising the levels of PPi could have an...